-
Nov 29, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Katherine L. Tuttle
Skip to main content Video Published: Views: 44 Likes: 0 Average (ratings) AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference.
-
Nov 28, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Marc P. Bonaca |Filippo L Gurgoglione
AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD). Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).
-
Nov 28, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Stephen Nicholls |Marc P. Bonaca
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).
-
Nov 28, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Stephen Nicholls |Marc P. Bonaca
AHA Conference 2024 - Safety and efficacy outcomes of muvalaplin (Eli Lilly and Company) in adults with elevated lipoprotein(a) at high risk for cardiovascular events. Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from KRAKEN (NCT05563246).
-
Nov 27, 2024 | 
radcliffecvrm.com | Harold Bays |Lydia Alexander |Harriette Van Spall
Video Published: Views: 36 Likes: 0 Average (ratings) AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events. Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).
-
Nov 27, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Marianna Fontana |Andrew Coats |Milind Y. Desai
Video Published: Views: 34 Likes: 0 Average (ratings) AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).
-
Nov 26, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Andrew Coats |Julia Grapsa
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial. Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Nov 19, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Mikhail Kosiborod |Julia Grapsa |Milind Y. Desai
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone. Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).
-
Nov 18, 2024 | 
radcliffecvrm.com | Harriette Van Spall |Harold Bays |Mikhail Kosiborod
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile. Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD). The FLOW trial (NCT03819153) is designed to assess the effect of semaglutide as compared to placebo in patients with chronic kidney disease and type 2 diabetes.
